Compare RUN & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | WGS |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Miscellaneous | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 4.6B |
| IPO Year | 2015 | N/A |
| Metric | RUN | WGS |
|---|---|---|
| Price | $12.29 | $78.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 7 |
| Target Price | $20.11 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 10.4M | 764.0K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | N/A |
| Revenue This Year | N/A | $29.98 |
| Revenue Next Year | $12.03 | $24.85 |
| P/E Ratio | ★ $6.77 | $1,251.58 |
| Revenue Growth | ★ 12.97 | N/A |
| 52 Week Low | $5.38 | $55.17 |
| 52 Week High | $22.44 | $170.87 |
| Indicator | RUN | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 30.56 | 37.47 |
| Support Level | $9.56 | $78.80 |
| Resistance Level | $21.35 | $95.94 |
| Average True Range (ATR) | 1.46 | 5.61 |
| MACD | -0.97 | 0.25 |
| Stochastic Oscillator | 8.10 | 40.30 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.